Skip to content

Efficacy and safety of remazolam in hysteroscopy

Efficacy and safety of remazolam in hysteroscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068576
Enrollment
Unknown
Registered
2023-02-23
Start date
2023-03-01
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial lesions

Interventions

Remazolam group and propofol group:The induction dose of rimazolam was 0.2mg/kg/min, and MOAA/S score was performed every 20 seconds. When MOAA/S=1, the maintenance dose was adjusted by 1 mg/kg/h, and
propofol group :The induced dose of propofol is 2mg/kg/min, and the MOAA/S score is performed every 20 seconds. When the MOAA/S = 1 minute, the maintenance dose is adjusted to 2mg/kg/h, and the opera

Sponsors

Hangzhou Women's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients aged 18-65, ASA grade I-II, body mass index (BMI)18-30kg/m2, selected for hysteroscopy, volunteered to participate in the study and signed informed consent, willing to comply with the study requirements.

Exclusion criteria

Exclusion criteria: Patients with a history of allergies to benzodiazepines, opioids, or certain medications; Long-term use of benzodiazepines or opioids; Complicated with heart, brain, lung and other important organ diseases; Long-term use of antidepressants, anti-anxiety drugs and pain relievers; Patients with a history of drug or alcohol abuse; Bradycardia (heart rate < 60bpm) or hypotension (systolic blood pressure < 100mmHg); Patients with severe respiratory diseases (obstructive sleep apnea syndrome, acute respiratory infections, acute episodes of chronic obstructive pulmonary disease, uncontrolled asthma, etc.); Patients with mental disorders (schizophrenia, mania, bipolar disorder, mental disorders, etc.); Any patient with cognitive impairment or who is unable to provide informed consent; Dyspnea (grade IV Mallampati score); Unwilling to continue to participate

Design outcomes

Primary

MeasureTime frame
onset time;Awakening time;Departure time;

Secondary

MeasureTime frame
Drug dosage;Incidence rate of adverse events;

Countries

China

Contacts

Public ContactBinZhu

Hangzhou Women’s Hospital

13758136317@163.com13758136317

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026